Biography
She has worked at UCSF to develop interdisciplinary teams of clinicians and researchers to bring the best care to patients and find the best platform to integrate translational research and improve the delivery of breast cancer care. In 2005, she received the NCI SPORE Investigator of the Year Award, an internationally recognized honor and designation.
She is the Principal Investigator of the I-SPY TRIAL program, a multi-site neoadjuvant clinical trial that has evolved into a model for translational research and innovation in clinical trial design.
Dr. Esserman launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.
Dr. Esserman is nationally and internationally known as a leader in the field of breast cancer and has published over 200 articles in peer-reviewed journals covering all aspects of breast health including information systems, immunology, decision making, health policy and the use of imaging. She speaks extensively at public and private forums within the U.S. and internationally. Overall, Dr. Esserman's research and writing tends to focus on the goal of giving patients better access to accurate information so that they can become partners in their health care.
She was a member of President Obama’s Council of Advisors on Science and Technology (PCAST) Working Group on Advancing Innovation in Drug Development and Evaluation, which studied how the federal government can best support science-based innovation in the process of drug development and regulatory evaluation. In addition, she was a contributing member of a “taskforce” for President Obama’s Council of Advisors on Science and Technology.
Dr. Esserman received her Bachelor's degree in History of Science from Harvard University and completed her M.D. at Stanford University. She completed her surgery residency and oncology fellowship at Stanford University Medical Center. After her training, she joined the faculty at Stanford and received a Hartford fellowship to attend Stanford Business School where she received her M.B.A. in 1993. She then joined the faculty at the University of California, San Francisco.
Education
1974-77, Harvard University, A.B.
1978-83, Stanford University, M.D.
1983-85, Stanford University School of Medicine, Resident, General Surgery
1988-90, Stanford University School of Medicine, Resident, General Surgery
1990-91, Stanford University School of Medicine, Chief Resident, General Surgery
1991-93, Stanford University, M.B.A.
Board Certifications
American Board of Surgery - General Surgery - 1992
Collaboration Interests
I am interested in:
- policy change
Clinical Expertise
DCIS (Ductal Carcinoma in situ)
Inflammatory Breast Cancer
Invasive Breast Cancer
LCIS (Lobular Carcinoma in situ)
Lumpectomy/Partial Mastectomy
Lymphadenectomy
Mastectomy
Recurrent Breast Cancer
Sentinel Lymph Node Biopsy
Wire Localization Surgery
Clinical Trials
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (NCT03053193)Related Conditions: Breast Cancer| Start Date: | End Date:
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379)Related Conditions: Breast Cancer, Breast Tumor, Angiosarcoma, Triple-Negative Breast Cancer, HER2, Hormone Receptor Negative Tumor, Neoplasms| Start Date: | End Date:
- Related Conditions: COVID-19, Respiratory Distress Syndrome| Start Date: | End Date:
- Related Conditions: Breast Cancer, Cancer, General| Start Date: | End Date:
- Related Conditions: Carcinoma, Intraductal, Noninfiltrating, Immunotherapy| Start Date: | End Date:
- Related Conditions: Breast Cancer| Start Date: | End Date:
- Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery (NCT00033397)Related Conditions: Breast Cancer| Start Date: | End Date:
- Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (NCT00416403)Related Conditions: Breast Cancer| Start Date: | End Date:
- Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction (NCT01258296)Related Conditions: Postoperative Pain| Start Date: | End Date:
- Related Conditions: Breast Cancer| Start Date: | End Date:
- Statins and Breast Cancer Biomarkers (NCT00914017)Related Conditions: Breast Cancer| Start Date:
Program Affiliations
- UCSF Center of Excellence for Breast Cancer Care
- UCSF Breast Care Center
- UCSF Helen Diller Comprehensive Cancer Center
Translational Co-Lead: Dr. Laura Esserman, is internationally recognized for her leadership of the ground-breaking I-SPY2 clinical trial and as an advocate for de-escalation of treatment for DCIS, and the initiation of the virtual preference pragmatic personalized screening trial (WISDOM) seeking to personalize the approach to screening. Her work in breast cancer spans the spectrum from public policy issues to basic science and the impact of both on the delivery of clinical care. Dr. Esserman has mentored 36 post-doctoral or clinical fellows during her career. She developed and runs a post-baccalaureate program that has trained 123 students over the past 15 years, most of whom have gone on to careers in medicine.
Dr. Esserman’s broad research interests provide exceptional opportunities for multidisciplinary training across the three themes, through clinical trials and biomarker studies on screening, prevention and treatment of breast cancer, many of which focus on improving healthcare value. Another fundamental and scalable effort is the implementation of systems to integrate care and research.
In the News
Grants and Funding
- WISDOM: A platform to optimize subtype-specific screening and prevention | NIH | 2024-09-11 - 2029-08-31 | Role: Principal Investigator
- The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes | NIH | 2017-09-08 - 2028-06-30 | Role: Principal Investigator
- RISE UP for Breast Cancer 2026 | NIH | 2026-02-09 - 2027-01-31 | Role: Principal Investigator
- RISE UP for Breast Cancer | NIH | 2024-09-01 - 2025-08-31 | Role: Principal Investigator
- Surgical Oncology Training Grant | NIH | 2020-07-15 - 2025-06-30 | Role: Principal Investigator
- Extending the Diversity, Reach, and Generalizability of the WISDOM Study | NIH | 2020-03-01 - 2025-02-28 | Role: Principal Investigator
- Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers | NIH | 2015-09-16 - 2021-08-31 | Role: Principal Investigator
- Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes | NIH | 2014-09-18 - 2020-08-31 | Role: Principal Investigator
- Integrated Biomarkers to Characterize Breast Cancer Risk | NIH | 2004-09-20 - 2011-06-30 | Role: Principal Investigator
Research Interests
- BRCA1 Protein
- BRCA2 Protein
- Breast Diseases
- Breast Neoplasms
- Male
- Mastectomy
- Segmental
- Ultrasonography
- Mammary
- Cancer Vaccines
- Genes
- Tumor Suppressor
- Oncogenes
- Precancerous Conditions
- Infiltrating Duct Carcinoma
- Intraductal Carcinoma
- Noninfiltrating Carcinoma Lobular
Publications
- WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.| |
PubMed
- Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, study.| |
PubMed
- Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.| |
PubMed
- A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.| |
PubMed
- Screening for Breast Cancer-Reply.| |
PubMed
- Author Correction: Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.| |
PubMed
- Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue.| |
PubMed
- Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.| |
PubMed
- Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.| |
PubMed
- Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.| |
PubMed